Targeting Mitochondrial DNA with a Platinum-Based Anticancer Agent
Name
Lippard_Targeting mitochondrial.pdf
Size
1.06 MB
Format
Adobe PDF
Checksum (MD5)
f3501bad31b52365aea7e7a8fe2ea4b1
Author(s)
Wisnovsky, Simon P.
Wilson, Justin J.
Radford, Robert J.
Pereira, Mark P.
Chan, Maria R.
Laposa, Rebecca R.
Lippard, Stephen J.
Kelley, Shana O.
Date Issued
October 2013
Journal
Chemistry and Biology
Publisher
Elsevier
Citation
Wisnovsky, Simon P., Justin J. Wilson, Robert J. Radford, Mark P. Pereira, Maria R. Chan, Rebecca R. Laposa, Stephen J. Lippard, and Shana O. Kelley. “Targeting Mitochondrial DNA with a Platinum-Based Anticancer Agent.” Chemistry & Biology 20, no. 11 (November 2013): 1323–1328. © 2013 Elsevier Ltd.
Version
Final published version
Abstract
An analog of the anticancer drug cisplatin (mtPt) was delivered to mitochondria of human cells using a peptide specifically targeting this organelle. mtPt induces apoptosis without damaging nuclear DNA, indicating that mtDNA damage is sufficient to mediate the activity of a platinum-based chemotherapeutic. This study demonstrates the specific delivery of a platinum drug to mitochondria and investigates the effects of directing this agent outside the nucleus.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.chembiol.2013.08.010
